tetano
Editor, Senior Moderator
Acta Pharm Sin B
. 2025 May;15(5):2498-2510.
doi: 10.1016/j.apsb.2025.02.028. Epub 2025 Mar 10. Anti-SARS-CoV-2 prodrug ATV006 has broad-spectrum antiviral activity against human and animal coronaviruses
Tiefeng Xu[SUP] 1 [/SUP], Kun Li[SUP] 2 [/SUP], Siyao Huang[SUP] 1 [/SUP], Konstantin I Ivanov[SUP] 3 [/SUP], Sidi Yang[SUP] 3 [/SUP], Yanxi Ji[SUP] 1 [/SUP], Hanwei Zhang[SUP] 1 [/SUP], Wenbin Wu[SUP] 1 [/SUP], Ye He[SUP] 4 [/SUP], Qiang Zeng[SUP] 1 [/SUP], Feng Cong[SUP] 5 [/SUP], Qifan Zhou[SUP] 6 [/SUP], Yingjun Li[SUP] 7 6 [/SUP], Jian Pan[SUP] 1 [/SUP], Jincun Zhao[SUP] 3 7 [/SUP], Chunmei Li[SUP] 1 [/SUP], Xumu Zhang[SUP] 6 8 [/SUP], Liu Cao[SUP] 1 [/SUP], Deyin Guo[SUP] 1 3 7 2 [/SUP]
Affiliations
Coronavirus-related diseases pose a significant challenge to the global health system. Given the diversity of coronaviruses and the unpredictable nature of disease outbreaks, the traditional "one bug, one drug" paradigm struggles to address the growing number of emerging crises. Therefore, there is an urgent need for therapeutic agents with broad-spectrum anti-coronavirus activity. Here, we provide evidence that ATV006, an anti-SARS-CoV-2 nucleoside analog targeting RNA-dependent RNA polymerase (RdRp), has broad antiviral activity against human and animal coronaviruses. Using mouse hepatitis virus (MHV) and human coronavirus NL63 (HCoV-NL63) as a model, we show that ATV006 has potent prophylactic and therapeutic activity against murine coronavirus infection in vivo. Remarkably, ATV006 successfully inhibits viral replication in mice even when administered 96 h after infection. Due to its oral bioavailability and potency against multiple coronaviruses, ATV006 has the potential to become a useful antiviral agent against SARS-CoV-2 and other circulating and emerging coronaviruses in humans and animals.
Keywords: Animal coronaviruses; Antiviral therapy; Broad-spectrum antiviral activity; Human coronaviruses; In vivo; Oral bioavailability; RNA-dependent RNA polymerase (RdRp); SARS-CoV-2.
. 2025 May;15(5):2498-2510.
doi: 10.1016/j.apsb.2025.02.028. Epub 2025 Mar 10. Anti-SARS-CoV-2 prodrug ATV006 has broad-spectrum antiviral activity against human and animal coronaviruses
Tiefeng Xu[SUP] 1 [/SUP], Kun Li[SUP] 2 [/SUP], Siyao Huang[SUP] 1 [/SUP], Konstantin I Ivanov[SUP] 3 [/SUP], Sidi Yang[SUP] 3 [/SUP], Yanxi Ji[SUP] 1 [/SUP], Hanwei Zhang[SUP] 1 [/SUP], Wenbin Wu[SUP] 1 [/SUP], Ye He[SUP] 4 [/SUP], Qiang Zeng[SUP] 1 [/SUP], Feng Cong[SUP] 5 [/SUP], Qifan Zhou[SUP] 6 [/SUP], Yingjun Li[SUP] 7 6 [/SUP], Jian Pan[SUP] 1 [/SUP], Jincun Zhao[SUP] 3 7 [/SUP], Chunmei Li[SUP] 1 [/SUP], Xumu Zhang[SUP] 6 8 [/SUP], Liu Cao[SUP] 1 [/SUP], Deyin Guo[SUP] 1 3 7 2 [/SUP]
Affiliations
- PMID: 40487635
- PMCID: PMC12144996
- DOI: 10.1016/j.apsb.2025.02.028
Coronavirus-related diseases pose a significant challenge to the global health system. Given the diversity of coronaviruses and the unpredictable nature of disease outbreaks, the traditional "one bug, one drug" paradigm struggles to address the growing number of emerging crises. Therefore, there is an urgent need for therapeutic agents with broad-spectrum anti-coronavirus activity. Here, we provide evidence that ATV006, an anti-SARS-CoV-2 nucleoside analog targeting RNA-dependent RNA polymerase (RdRp), has broad antiviral activity against human and animal coronaviruses. Using mouse hepatitis virus (MHV) and human coronavirus NL63 (HCoV-NL63) as a model, we show that ATV006 has potent prophylactic and therapeutic activity against murine coronavirus infection in vivo. Remarkably, ATV006 successfully inhibits viral replication in mice even when administered 96 h after infection. Due to its oral bioavailability and potency against multiple coronaviruses, ATV006 has the potential to become a useful antiviral agent against SARS-CoV-2 and other circulating and emerging coronaviruses in humans and animals.
Keywords: Animal coronaviruses; Antiviral therapy; Broad-spectrum antiviral activity; Human coronaviruses; In vivo; Oral bioavailability; RNA-dependent RNA polymerase (RdRp); SARS-CoV-2.